OmniAb Inc. (OABI) - Total Assets
Based on the latest financial reports, OmniAb Inc. (OABI) holds total assets worth $309.69 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See OmniAb Inc. net assets for net asset value and shareholders' equity analysis.
OmniAb Inc. - Total Assets Trend (2019–2024)
This chart illustrates how OmniAb Inc.'s total assets have evolved over time, based on quarterly financial data. Check OmniAb Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
OmniAb Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
OmniAb Inc.'s total assets of $309.69 Million consist of 20.9% current assets and 79.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.5% |
| Accounts Receivable | $5.27 Million | 1.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $138.06 Million | 42.4% |
| Goodwill | $83.98 Million | 25.8% |
Asset Composition Trend (2019–2024)
This chart illustrates how OmniAb Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OABI market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OmniAb Inc.'s current assets represent 20.9% of total assets in 2024, an increase from 3.0% in 2019.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 67.0% of total assets, a decrease from 94.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 42.4% of total assets.
OmniAb Inc. Competitors by Total Assets
Key competitors of OmniAb Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
OmniAb Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.00 | 4.62 | 1.17 |
| Quick Ratio | 4.96 | 4.62 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $53.07 Million | $52.21 Million | $2.37 Million |
OmniAb Inc. - Advanced Valuation Insights
This section examines the relationship between OmniAb Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.78 |
| Asset Growth Rate (YoY) | -13.2% |
| Total Assets | $325.56 Million |
| Market Capitalization | $254.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values OmniAb Inc.'s assets below their book value (0.78x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: OmniAb Inc.'s assets decreased by 13.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OmniAb Inc. (2019–2024)
The table below shows the annual total assets of OmniAb Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $325.56 Million | -13.24% |
| 2023-12-31 | $375.23 Million | -10.92% |
| 2022-12-31 | $421.21 Million | +38.34% |
| 2021-12-31 | $304.46 Million | +3.08% |
| 2020-12-31 | $295.38 Million | +12.60% |
| 2019-12-31 | $262.32 Million | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more